ULTOMIRIS (ravulizumab, Alexion) is now listed on the PBS as a Section 100 item for the treatment of the autoimmune disease generalised myasthenia gravis.
Susan White, chairperson of Myasthenia Alliance Australia, said it is great news for patients who will now have PBS access to a new treatment.
"It's been a long journey to see this medicine reach the PBS and we thank the government for making this innovative medicine accessible for Australians," White said.
Other new PBS listings this month are glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx, Roche) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma, and an expanded listing for incobotulinumtoxinA (Xeomin, Merz Therapeutics) for the treatment of chronic sialorrhea, a condition that causes excessive saliva.
Indications for nivolumab and ipilimumab have also been expanded for the treatment of advanced or metastatic cancers.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Mar 26
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Mar 26
